Karnataka Defends Closure of Jan Aushadhi Kendras in Govt Hospitals

Bengaluru, August 7, 2025 — Karnataka Health Minister Dinesh Gundu Rao has defended the state government’s decision to discontinue Jan Aushadhi Kendras (JAKs) within government hospital premises. His explanation came in response to concerns raised by Union Health Minister J.P. Nadda regarding access to affordable medicines through this central scheme.

 

According to Minister Rao, the move aims to ensure patients receive free and guaranteed essential medicines from public hospitals’ own supplies, eliminating the risk of being directed elsewhere for drug purchases. Doctors are now instructed to prescribe only drugs that are part of the Essential Medicines List (EML) and available in the hospital stock, supplied via the http://Karnataka State Medical Supplies CorporationKarnataka State Medical Supplies Corporation (KSMSCL). Funds are allocated for additional local procurement, if needed.

 

Rao clarified that this change applies only to JAKs located within hospital campuses. Over 1,417 Jan Aushadhi Kendras still operate elsewhere in Karnataka, with only 184 previously located inside hospitals, which have now been phased out. Citizens may continue accessing JAKs outside government premises.

Rao emphasized Karnataka’s commitment to improving public health infrastructure, ensuring rational drug usage, and strengthening medical supply chains—all to benefit underprivileged and marginalized patients.

While acknowledging the affordability of medicines through the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)—which offers generics at 50–80% lower prices—Rao requested the Pharma and Medical Bureau of India (PMBI) to supply medicines to the Karnataka Health Department at the same rates offered to JAKs, bolstering the state’s free drug supply efforts.

 

Rao emphasized Karnataka’s commitment to improving public health infrastructure, ensuring rational drug usage, and strengthening medical supply chains—all to benefit underprivileged and marginalized patients.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre